NASDAQ:GRTX - Galera Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $15.00
  • Forecasted Upside: 38.50 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$10.83
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Galera Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.00
▲ +38.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $21.00 and a low forecast of $9.00. The average price target represents a 38.50% upside from the last price of $10.83.
Hold
The current consensus among 1 investment analysts is to hold stock in Galera Therapeutics. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2020Credit Suisse GroupBoost Price TargetNeutral$8.00 ➝ $9.00Low
i
10/28/2020Smith Barney CitigroupBoost Price Target$18.00 ➝ $21.00High
i
7/29/2020Credit Suisse GroupLower Price TargetNeutral$14.00 ➝ $8.00Low
i
12/2/2019BTIG ResearchInitiated CoverageBuy$30.00High
i
12/2/2019Credit Suisse GroupInitiated CoverageNeutral$14.00High
i
12/2/2019CitigroupInitiated CoverageBuy$20.00High
i
12/2/2019Bank of AmericaInitiated CoverageBuy$15.00High
i
(Data available from 12/3/2015 forward)
Galera Therapeutics logo
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $10.83
$10.71
$11.79

50 Day Range

MA: $10.71
$8.02
$12.81

52 Week Range

Now: $10.83
$5.58
$19.50

Volume

12,963 shs

Average Volume

53,530 shs

Market Capitalization

$270.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A